📑 Table of Contents▼

GEMoaB Monoclonals
TypeGmbH
IndustryBiotechnology
Pharmaceutical
Founded2011
FounderGerhard Ehninger, Michael Bachmann
HeadquartersDresden, Germany,
Key people
Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger (CMO)[1]
ProductsGEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA
Revenuen.a.
Websitewww.gemoab.com

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[2][3] It was acquired by the new company AvenCell Therapeutics in 2021.[4][5]

Company background

edit
See also: Chimeric antigen receptor T cell

To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[6]

Scientific and strategic board

edit

The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).[7]

Co-operations

edit

Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[8]

Drugs currently under development

edit
  • GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[9][10]
  • GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[11]
  • UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
  • UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours

Literatur

edit
  • Mitwasi, N; Feldmann, A; Arndt, C; Koristka, S; Berndt, N; Jureczek, J; Loureiro, LR; Bergmann, R; Máthé, D; Hegedüs, N; Kovács, T; Zhang, C; Oberoi, P; Jäger, E; Seliger, B; Rössig, C; Temme, A; Eitler, J; Tonn, T; Schmitz, M; Hassel, JC; Jäger, D; Wels, WS; Bachmann, M (2020). ""UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells". Sci Rep. 10: 2141. doi:10.1038/s41598-020-59082-4. PMC 7005792. PMID 32034289..
  • Loff, S.; Meyer, J.-E.; Dietrich, J.; Spehr, J.; Julia, R.; von Bonin, M.; Gründer, C.; Franke, K.; Feldmann, A.; Bachmann, M.; Ehninger, G.; Ehninger, A.; Cartellieri, M. (2018). "Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia". Blood. 132: 964–964. doi:10.1182/blood-2018-99-113288.
  • Arndt, C; Feldmann, A; Koristka, S; Schäfer, M; Bergmann, R; Mitwasi, N; Berndt, N; Bachmann, D; Kegler, A; Schmitz, M; Puentes-Cala, E; Soto, JA; Ehninger, G; Pietzsch, J; Liolios, C; Wunderlich, G; Kotzerke, J; Kopka, K; Bachmann, M (2019). "A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR". Oncoimmunology. 8 1659095. doi:10.1080/2162402X.2019.1659095. PMC 6791425. PMID 31646084..
  • Arndt, C; von Bonin, M; Cartellieri, M; Feldmann, A; Koristka, S; Michalk, I; Stamova, S; Bornhäuser, M; Schmitz, M; Ehninger, G; Bachmann, M (2013). "Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells". Leukemia. 27: 964–7. doi:10.1038/leu.2013.18. PMID 23325142..

See also

edit

References

edit
  1. ^ Leadership Team Leadership Team Archived 14 July 2021 at the Wayback Machine, Company Website, Retrieved: July 15, 2021
  2. ^ Get to know GEMoaB[permanent dead link], Company Website, Retrieved: May 11, 2020
  3. ^ "GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias". chemie-link.de. 9 March 2020. Retrieved 11 May 2020.[permanent dead link]
  4. ^ "Clinical-stage biopharma company targets hard-to-treat cancers". AvenCell. Retrieved 12 February 2024.
  5. ^ "Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company". Blackstone. 22 June 2021. Retrieved 12 February 2024.
  6. ^ Cartellieri, M.; Feldmann, A.; et al. (2016). "Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts". Blood Cancer Journal. 6: e458. doi:10.1038/bcj.2016.61. PMC 5022178. PMID 27518241.
  7. ^ Scientific and Strategic Advisory Board[permanent dead link], Company Website, Retrieved: May 11, 2020
  8. ^ Our Partners[permanent dead link], Company Website, Retrieved: May 11, 2020
  9. ^ AML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020
  10. ^ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020
  11. ^ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020
edit